Dear DPA Members,

I am very pleased to invite you to register for our educational program sponsored by Teva Pharmaceuticals. This program is exclusively for DPA members, so therefore please do not invite or share registration information to anyone outside of DPA. Space limitation is set by the sponsor and no walk-ins can be accommodated.

You only need to register on the DPA website to attend this program

Event DETAILS

WHEN: Wednesday, January 14th, 2026, at 6:00 PM

WHERE (NEW LOCATION): Beatrix, 272 Oakbrook Center, Oak Brook, IL 60523 

MEETING AGENDA:

6:00pm – Social Time & Registration

6:30pm-7:15pm – Teva Pharmaceutical presented by Keith Nguyen, PharmD, BCPS, BCCCP, Medical Science Liaison

7:30pm-8:30pm – Continuing Pharmacy Education Program presented by Dr. Sky Harrigfeld, PharmD.

8:30pm-9:00pm – General announcements

Presentation 1: Sponsored by Teva Pharmaceuticals

Program Title: “Pediatric Migraine and SPACE-EM”, Recent data from the SPACE trials supporting the use of Ajovy in pediatric patients.

Speaker: KeithNguyen, PharmD, BCPS, BCCCP, Medical Science Liaison, Teva Pharmaceuticals

Presentation 2: DPA Sponsored Continuing Pharmacy Education

Program Title: “Liver Let Die? Not Quite”, Updates in MASLD Nomenclature, Screening, and Management

Speaker: Sky Harrigfeld, PharmD, PGY2 Ambulatory Care Pharmacy Resident | UIC Retzky College of Pharmacy

Educational Objectives:

Target Audience: Pharmacists and Pharmacy Technicians

Pharmacist should be able to:

1. Discuss updated nomenclature for metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic-dysfunction associated steatohepatitis (MASH).
2. Describe strategies for MASLD and MASH screening.
3. Summarize pharmacologic and non-pharmacologic management strategies of MASLD

Pharmacy Technician should be able to:

1. Discuss updated nomenclature for metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic-dysfunction associated steatohepatitis (MASH).
2. Describe strategies for MASLD and MASH screening.
3. Summarize pharmacologic and non-pharmacologic management strategies of MASLD